Vitex agnus-castus Ze 440 extract in the therapy of cyclic mastodynia in women with non-tumor breast damage




cyclic mastalgia, pain syndrome, Prefemin, Vitex agnus-castus


Cyclic mastalgia of varying intensity occurs every month in at least 70% of women, persistent pain in the mammary glands of moderate and severe degree is occur in about 50% of patients with benign mastopathy. The cause of mastodynia is the morphofunctional rearrangement of the glandular and stromal components of tissues with the expansion of ducts and proliferation of epithelial structures due to a lack of progesterone and an increase in prolactin levels. Therapy for cyclical and chronic mastalgia is empirical and not always effective. Herbal medicine with Vitex agnus-castus is a reasonable alternative to hormonal treatment for women suffering from cyclic mastalgia in combination with other manifestations of premenstrual syndrome. The main effect of such drugs is an increase of luteinizing hormone and progesterone synthesis, effect on the hypothalamic-pituitary system, prolactin and endorphins release, which can increase the level of endogenous opioids.
Purpose of the study: to study the effect of the phytopreparation Prefemin (Vitex agnus-castus extract Ze 440) on the intensity of chronic pain syndrome in women with diffuse non-tumor breast lesion.
Materials and methods. The study involved 30 women aged 22 to 43 years with various types of benign breast diseases and chest pain lasting at least 3 months. In 12 patients there was diffuse fibroadenoma, in 18 – diffuse cystofibroadenoma (small cystic variant) and duct ectasia.
Results. Therapy with Prefemin (Ze 440) allowed to completely eliminate pain syndrome in 93.3% of women and to reduce the frequency of mastodynia in the group with moderate severity in 90.0% of patients with diffuse fibroadenoma and cystofibroadenoma.
Conclusions. Phytopreparation Prefemin, which is obtained from the medicinal plant Vitex agnus-castus, has demonstrated high efficacy in the mastalgia treatment in women with diffuse fibrocystic breast disease. This drug was well tolerated and there were no side effects.

Author Biographies

O.O. Kovaliov, Zaporizhzhia Medical Academy of Postgraduate Education of the MoH of Ukraine

MD, professor, head of the Oncology Department

L.I. Alivapova, Medical Center “Ulis”

Mammologist surgeon


  1. Ciotta, L., Pagano, I., Stracquadanio, M., et al. “Psychic aspects of the premenstrual dysphoric disorders. New therapeutic strategies: our experience with Vitex agnus castus.” Minerva Ginecol 63 (2011): 237–45.
  2. Eltbogen, R., Litschgi, M., Gasser, U., et al. “Vitex agnus-castus extract (Ze 440) improves symptoms in women with menstrual cycle irregularities.” Planta Med 80 (2014): SL19.
  3. Eltbogen, R., et al. “Vitex-agnus-castus-Extrakt (Ze 440) zur Symptom-behandlung bei Frauen mit menstruellen Zyklusstörungen.” Journal für Gynäkologische Endokrinologie 25.2 (2015): 10–15.
  4. Freeman, E.W., Rickets, K., Sammel, M.D., et al. “Time to relapse after short- or long-term treatment of severe premenstrual syndrome.” Arch Gen Psychiatry 66 (2009): 537–44.
  5. He, Z., Chen, R., Zhou, Y., et al. “Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multicenter placebo-controlled study in China.” Maturitas 63.1 (2009): 99–103.
  6. Johnson, K.M., Bradley, K.A., Bush, K., et al. “Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes.” J Gen Intern Med 21 Suppl. 3 (2006): 70–5.
  7. Li, S., Qiu, S., Yao, P., et al. “Compounds from the fruits of the popular European medicinal plant Vitex agnus-castus in chemoprevention via NADP (H): Quinone oxidoreductase type 1 induction.” Evid Based Complement Alternat Med 2013 (2013): 432829.
  8. Lopez, L.M., Kaptein, A., Helmerhorst, F.M. “Oral contraceptives containing drospirenone for premenstrual syndrome.” Cochrane Database Syst Rev 2 (2012): CD006586.
  9. Maharaj, S., Trevino, K. “A comprehensive review of treatment options for premenstrual syndrome and premenstrual dysphoric disorder.” J Psychiatr Pract 21 (2015): 334–50.
  10. Marjoribanks, J., Brown, J., O’Brien, P.M., et al. “Selective serotonin reuptake inhibitors for premenstrual syndrome.” Cochrane Database Syst Rev 6 (2013): CD001396.
  11. Momoeda, M., Sasaki, H., Tagashira, E., et al. “Efficacy and safety of Vitex agnus-castus extract for treatment of premenstrual syndrome in Japanese patients: A prospective, open-label study.” Adv Ther 31 (2014): 362–73. 24604699
  12. Mousavi, P., Zaheri, H., Najar, S., et al. “Effect of Vitagnus on premenstrual syndrome.” IJOGI 17 (2015): 1–9.
  13. Nevatte, T., O’Brien, P.M., Backstrom, T., et al. “ISPMD consensus on the management of premenstrual disorders.” Arch Womens Ment Health 16 (2013): 279–91.
  14. O’Brien, S., Rapkin, A., Dennerstein, L., et al. “Diagnosis and management of premenstrual disorders.” BMJ 342 (2011): d2994.
  15. Posadzki, P., Watson, L.K., Ernst, E. “Adverse effects of herbal medicines: An overview of systematic reviews.” Clin Med (Lond) 13 (2013): 7–12.
  16. Preece, P.E., Mansel, R.E., Hughes, L.E. “Mastalgia: psychoneurosis or organic disease?” Br Med J 1.6104 (1978): 29–30.
  17. Royal College of Obstetricians & Gynaecologists. “Management of premenstrual syndrome.” Green-Top Guideline 48 (2007): 1–16.
  18. Ryu, A., Kim, T.H. “Premenstrual syndrome: a mini review.” Maturitas 82 (2015): 436–40.
  19. Salzman, B., Fleegle, S., Tully, A.S. “Common breast problems.” Am Fam Physician 86.4 (2012): 343–9.
  20. Schellenberg, R., Zimmermann, C., Drewe, J., et al. “Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome.” Phytomedicine 19 (2012): 1325–31.
  21. Smith, R.L., Pruthi, S., Fitzpatrick, L.A. “Evaluation and management of breast pain.” Mayo Clin Proc 79.3 (2004): 353–72.
  22. van Die, M.D., Burger, H.G., Teede, H.J., Bone, K.M. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Medica 79.7 (2013): 562–75.
  23. Verkaik, S., Kamperman, A.M., van Westrhenen, R., Schulte, P.F. “The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis.” American Journal of Obstetrics and Gynecology 2 (2017): 150–66.
  24. Webster, D.E., He, Y., Chen, S.N., et al. “Opioidergic mechanisms underlying the actions of Vitex agnus-castus L.” Biochem Pharmacol 81 (2011): 170–7.
  25. Zamani, M., Neghab, N., Torabian, S. “Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome.” Acta Med Iran 50 (2012): 101–6.



How to Cite

Kovaliov, O., & Alivapova, L. (2021). Vitex agnus-castus Ze 440 extract in the therapy of cyclic mastodynia in women with non-tumor breast damage. REPRODUCTIVE ENDOCRINOLOGY, (58), 79–82.



Tumors and pretumoral pathology